Arvinas Inc (ARVN)

Schlusskurs vom Vortag:

$32.48

Offen:

$33.12

24-Stunden-Volumen:

612.61K

Marktkapitalisierung:

$2.22B

Einnahmen:

$78.50M

Nettoeinkommen (Verlust:

$-367.30M

KGV:

-5.8014

EPS:

-5.59

Netto-Cashflow:

$-350.70M

1W Leistung:

+2.63%

1M Leistung:

-16.93%

6M Leistung:

+100.06%

1J Leistung:

+29.93%

1-Tages-Spanne:

$31.68

$33.15

52-Wochen-Spanne:

$13.57

$53.08

Arvinas Inc Stock (ARVN) Company Profile

Firmenname

Arvinas Inc

Sektor

Healthcare (1190)

Branche

Biotechnology (681)

Telefon

203-535-1456

Adresse

5 Science Park, 395 Winchester Avenue, New Haven, CT

Mitarbeiter

77

Twitter

@ArvinasInc

Nächster Verdiensttermin

2024-05-03

Neueste SEC-Einreichungen

ARVN's Discussions on Twitter

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-14	Herabstufung	Citigroup	Buy → Neutral
2024-02-01	Eingeleitet	Goldman	Buy
2023-12-19	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-12-06	Hochstufung	Jefferies	Hold → Buy
2023-11-20	Hochstufung	Guggenheim	Neutral → Buy
2023-10-23	Hochstufung	Wedbush	Neutral → Outperform
2023-06-26	Fortgesetzt	Oppenheimer	Outperform
2023-01-12	Herabstufung	Guggenheim	Buy → Neutral
2023-01-03	Herabstufung	Wells Fargo	Overweight → Equal Weight
2022-09-09	Eingeleitet	Barclays	Overweight
2022-06-21	Eingeleitet	Jefferies	Hold
2022-05-09	Herabstufung	Wedbush	Outperform → Neutral
2022-04-28	Eingeleitet	Credit Suisse	Outperform
2022-04-06	Eingeleitet	Morgan Stanley	Equal-Weight
2022-02-11	Fortgesetzt	BMO Capital Markets	Outperform
2022-02-10	Eingeleitet	Wells Fargo	Overweight
2022-01-19	Eingeleitet	Goldman	Buy
2021-12-07	Eingeleitet	Cowen	Outperform
2021-10-14	Eingeleitet	SVB Leerink	Outperform
2021-09-30	Eingeleitet	Stifel	Buy
2021-09-09	Eingeleitet	BofA Securities	Buy
2021-05-21	Eingeleitet	UBS	Buy
2021-04-21	Eingeleitet	Truist	Buy
2021-03-31	Eingeleitet	BMO Capital Markets	Outperform
2020-12-14	Hochstufung	Oppenheimer	Perform → Outperform
2020-06-01	Hochstufung	Citigroup	Neutral → Buy
2020-05-12	Eingeleitet	Oppenheimer	Perform
2019-12-19	Eingeleitet	H.C. Wainwright	Buy
2019-11-25	Eingeleitet	Guggenheim	Buy
2019-10-24	Hochstufung	Goldman	Neutral → Buy
2019-09-25	Eingeleitet	Wedbush	Outperform
2019-09-12	Eingeleitet	BMO Capital Markets	Outperform
2019-08-06	Eingeleitet	Cantor Fitzgerald	Overweight
2019-06-05	Herabstufung	Citigroup	Buy → Neutral
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2018-10-22	Eingeleitet	Citigroup	Buy
2018-10-22	Eingeleitet	Goldman	Neutral
2018-10-22	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Arvinas Inc Aktie (ARVN) Neueste Nachrichten

Why Earnings Season Could Be Great for Arvinas (ARVN)

Zacks Investment Research

Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

Zacks Investment Research

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

GlobeNewswire Inc.

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

Zacks Investment Research

Finanzdaten der Arvinas Inc-Aktie (ARVN)

Arvinas Inc (ARVN) Umsatz 2024

Arvinas Inc (ARVN) Nettogewinn 2024

Arvinas Inc (ARVN) Free Cashflow 2024

Arvinas Inc (ARVN) Gewinn je Aktie 2024